Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are typically loss-of-function mutations and not directly therapeutically targetable, central goals have been to elucidate mechanism and identify vulnerabilities created by these mutations. Here, we discuss emerging data that these mutations lead to the formation of aberrant residual SWI/SNF complexes that constitute a specific vulnerability and discuss the potential for exploiting these dependencies in SWI/SNF mutant cancers.
SWI/SNF complexes are evolutionarily conserved multisubunit complexes that utilize the energy of ATP hydrolysis to mobilize nucleosomes and remodel chromatin (Kassabov et al., 2003; Phelan et al., 1999) . These 2 MDa complexes are made up of 12-15 subunits; they contain one of the two catalytic ATPase subunits, SMARCA4/BRG1 or SMARCA2/BRM; several core subunits, including SMARCB1/SNF5/INI1/BAF47 and SMARCC1/ BAF155, that are present in all SWI/SNF complexes; and subunits present in only some variants, such as ARID1A and ARID1B, mutually exclusive subunits for BAF (BRG1-associated factor) varieties of the complexes, and PBRM1 and ARID2, specific for PBAF (polybromo BRG1-associated factor) varieties of the complexes (Wang et al., 1996; Wu et al., 2009) . SWI/SNF complexes interact with transcription factors, coactivators, and corepressors and are capable of mobilizing nucleosomes at target promoters and enhancers to modulate gene expression ( Figure 1) Tolstorukov et al., 2013; You et al., 2013) and have also been implicated in various types of DNA repair (Dykhuizen et al., 2013; Gong et al., 2006; Hara and Sancar, 2002; Park et al., 2006; Watanabe et al., 2014) .
With respect to a role in the control of gene expression, SWI/ SNF complexes have been shown to serve roles in the transcriptional regulation of lineage specification and development in numerous model systems. For example, SWI/SNF complexes contribute to the development of T cells (Chi et al., 2002; Wang et al., 2011b) , hepatocytes (Gresh et al., 2005) , oligodendrocytes (Yu et al., 2013) , and embryonic stem cell self-renewal and pluripotency (Gao et al., 2008; Ho et al., 2009 ). Specificity of SWI/SNF complexes in the control of these developmental programs is achieved in part through restricted expression and combinatorial assembly of variant SWI/SNF subunits. The SMARCD3 (BAF60C) subunit is expressed specifically in the embryonic heart, where it is essential for the control of cardiac development (Lickert et al., 2004) . Similarly, a switch from the PHF10 (BAF45A) and ACTL6A (BAF53A) subunits, which are expressed in neural stem cells, to DPF1 (BAF45B), DPF3 (BAF45C), and ACTL6B (BAF53B) sub-units is essential to control the transition of neural progenitors into postmitotic mature neurons Wu et al., 2007) . Such switching can modulate interaction with specific transcription factors (Kadam et al., 2000) and facilitates differential activation of transcriptional pathways. Ultimately, via combinatorial inclusion of variant subunits, several hundred versions of SWI/SNF complexes may exist (Wu et al., 2009 ) and serve instructive roles in the control of fate specification.
The first clue linking SWI/SNF complexes to cancer came in the late 1990s, when mutations of the gene encoding the SMARCB1 (SNF5/INI1/BAF47) subunit were identified in rhabdoid tumors (RTs), a rare but highly aggressive type of cancer that strikes young children (Biegel et al., 1999; Versteege et al., 1998) . Smarcb1 was subsequently validated as a bona fide and potent tumor suppressor in genetically engineered mouse models (Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000 Roberts et al., , 2002 . While this observation was first noted over a decade ago, it is only more recently via cancer genome sequencing studies that the high prevalence of SWI/SNF subunit mutations have been found in many types of cancer. At least nine genes encoding subunits of SWI/SNF complexes have been identified as recurrently mutated in cancers derived from nearly every tissue in the body, collectively occurring in 20% of all human cancers ( Figure 1) Shain and Pollack, 2013) . For example, inactivating mutations of ARID1A are prevalent in a wide variety of cancers, including 45% of ovarian clear cell and endometrioid carcinomas (Jones et al., 2010; Wiegand et al., 2010) ; 19% of gastric cancers (Wang et al., 2011a) ; 19% of bladder cancers (Gui et al., 2011) ; 14% of hepatocellular cancers (Guichard et al., 2012) ; 12% of melanomas (Hodis et al., 2012) ; and also less frequently in colorectal, lung, breast, pancreas, and several other cancer types Shain and Pollack, 2013) . SMARCA4 (BRG1), a catalytic ATPase and a core subunit of SWI/SNF complexes, is mutated in several cancer types, including lung (Medina et al., 2008; Reisman et al., 2003) , medulloblastoma (Parsons et al., 2011) , pancreatic cancer (Wong et al., 2000) , and, most recently, small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (Jelinic et al., 2014; Ramos et al., 2014; Witkowski et al., 2014) . Other subunits have also been found to be mutated in cancer, such as PRBM1 (BAF180) in renal carcinoma (Varela et al., 2011) and ARID2 in melanoma (Hodis et al., 2012) and hepatocellular carcinoma (Figure 1 ). The mechanisms by which mutation of each individual subunit promote oncogenesis and the function of mutated SWI/SNF complexes in cancer is now an active area of investigation.
Many studies have elucidated pathways that are regulated by SWI/SNF complexes and how disruption of these gene expression programs by subunit mutation promotes cancer. For example, SWI/SNF can bind to retinoblastoma (RB) and facilitate repression of RB target genes (Trouche et al., 1997) . SWI/SNF also interacts with MYC, both as an activator and as a repressor (Cheng et al., 1999; Nagl et al., 2006) . In part, via disruption of RB function, inactivation of SMARCB1 leads to downregulation of p16 INK4a and E2F targets, indicating that SWI/SNF plays a role in cell cycle regulation and differentiation Isakoff et al., 2005; Oruetxebarria et al., 2004) . Additionally, SWI/SNF complexes are required for specific regulation of interferon beta targets (Morozov et al., 2007; Ramirez-Carrozzi et al., 2009) . It has been shown that SWI/SNF complexes can bind to the promoters of roughly one-third of all genes (Ho et al., 2009; Tolstorukov et al., 2013) and the aforementioned represent only a few of numerous pathways that have been shown to be SWI/SNF dependent.
With respect to the chromatin mechanisms that underlie regulation of targets, a largely antagonistic functional relationship between SWI/SNF and PRC2 complexes has been identified (Ho et al., 2009; Kennison and Tamkun, 1988; Kia et al., 2008; Wilson et al., 2010) . Loss of SMARCB1 leads to upregulation of EZH2 as well as broad H3K27 trimethylation and repression of PRC2 targets, effects that are essential for cancer formation driven by SMARCB1 loss (Wilson et al., 2010 EZH2 may represent a therapeutic opportunity for SMARCB1 mutant cancers (Knutson et al., 2013) . While the mechanisms by which SWI/SNF mutations contribute to cancer are still being elucidated and the relative importance of contributions to transcriptional regulation versus DNA repair are still in question, mutation of SWI/SNF subunits in cancer likely contributes to cancer, at least in part, by perturbing the regulation of transcriptional pathways involved in control of proliferation and fate specification (Eroglu et al., 2014) .
It is interesting to note that, while loss-of-function SWI/SNF subunit mutations seem most prevalent in cancer, point mutations have also been described, such as a small number of SMARCA4 missense mutations in medulloblastoma (Parsons et al., 2011) . It is not yet understood whether these point mutations also result in loss of function of the protein, as in a classical tumor suppressor, or whether they result in partial loss, or even potentially oncogenic gain-of-function effects. Looking forward, elucidating the effects of these point mutations will likely provide further mechanistic understanding of the cancer-promoting activity of SWI/SNF mutations. However, from a therapeutic standpoint, as mutations in genes encoding SWI/SNF complex subunits are often loss of function, including nonsense, frameshift, and large deletions (Lee et al., 2012; Versteege et al., 1998; Wang et al., 2014b; Wilson and Roberts, 2011) , the products of the mutant genes themselves do not constitute obvious drug targets. Consequently, it is of great interest to identify specific vulnerabilities conferred by these mutations on cancer cells that have the potential to provide new therapeutic opportunities.
The Residual Complex: A New Class of Vulnerability
One attractive hypothesis to account for many subunits of a single complex mutated is that all of the mutations are essentially equivalent and result in inactivation of SWI/SNF complexes. However, several findings seemed in conflict with such a possibility. First, the consequences of inactivation of genes encoding SWI/SNF subunits in mice are fairly distinct. For example, while inactivation of Smarcb1 and Smarca4 both result in early embryonic lethality at embryonic day (E)3.5 (Guidi et al., 2001; Klochendler-Yeivin et al., 2000) , knockout of Arid1a leads to the absence of mesoderm and arrest at E6.5 (Gao et al., 2008) , silencing of Smarcd3 results in heart developmental defects (Lickert et al., 2004) , and Smarca2-deficient mice are viable (Reyes et al., 1998) . Consequently, subunit loss results in distinct developmental phenotypes. Second, loss of different subunits of the complexes is associated with different types of cancer. For example ARID1A is frequently mutated in ovarian cancer (Jones et al., 2010; Wiegand et al., 2010) ; SMARCA4, in lung cancer (Fukuoka et al., 2004; Medina et al., 2008; Reisman et al., 2003) ; PBRM1, in renal cancer (Varela et al., 2011) ; and SMARCB1, in RTs (Lee et al., 2012) , with only modest overlap, suggesting distinct consequences for mutation of different subunits. Consistent with this, conditional Smarcb1 deletion in mice results in formation of rhabdoid-like tumors and lymphomas (Roberts et al., 2002) while Smarca4 haploinsufficiency leads to mammary tumors (Bultman et al., 2008) . Third, it has been shown that SWI/SNF complexes can assemble without SMARCB1 (Doan et al., 2004) , SMARCA4 (Hoffman et al., 2014; Wilson et al., 2014) , or ARID1A , indicating that residual complexes remain despite tumor suppressor subunit loss. Consequently, an alternate hypothesis was proposed: that loss of tumor suppressor subunits results in aberrant residual complexes that, in turn, actively drive oncogenesis (Wang et al., 2009 ). Essentially, oncogenesis was not due to tumor suppressor loss per se but rather to gain of aberrantly functioning residual complexes.
Consistent with this hypothesis was the demonstration of an essential role for the residual complex in driving cancer formation in SMARCB1 mutant cancers. Specifically, rather than accelerating cancer, or having no effect due to redundancy, the proliferation of SMARCB1-deficient human RT lines was blocked on knockdown of SMARCA4, itself a tumor suppressor. In genetically engineered mouse models, inactivation of Smarca4 also blocked the in vivo tumor formation otherwise caused by Smarcb1 loss (Wang et al., 2009 ). These findings suggested that the functional activity of residual SWI/SNF complexes might be essential for cancer driven by SMARCB1 loss. However, SMARCB1 mutant cancers are quite rare, and whether this concept was similarly true for cancers mutant in other SWI/ SNF subunits was unknown. Additionally, since several SWI/ SNF subunits serve important roles in various cell types, it remained unclear whether there was a differential requirement for these subunits between SWI/SNF mutant cancers and normal cells, which would be necessary for a potential therapeutic approach based on targeted inhibition of residual complexes.
Recently, data from three large-scale screening publications Hoffman et al., 2014; Wilson et al., 2014) have provided some insight to this question; they suggest that an essential role for the residual complex extends to the wide spectrum of cancers harboring mutations in other subunits and also suggest that enhanced dependence on at least some residual complex members occurs in SWI/SNF mutant cancers. Project Achilles is a near-genome-scale small hairpin RNA screen against 11,000 genes performed in over 200 human cancer cell lines (Cheung et al., 2011) . Data from Project Achilles were used to search for dependencies created by SWI/SNF mutation. Within the cell lines in Project Achilles, genes encoding two SWI/ SNF subunits were mutated at sufficient frequency to enable a search for vulnerabilities. ARID1A was mutant in 18 of 165 cell lines, while SMARCA4 was mutant in 8 of 165 cell lines. Both of these comparisons resulted in novel insights-in both cases, the number one dependence was on a related SWI/SNF subunit.
In ARID1A mutant cancer cells, ARID1B was identified as the number one dependency, suggesting that, in the setting of ARID1A mutation, residual SWI/SNF complexes become specifically and differentially reliant on ARID1B . ARID1A and ARID1B are 60% identical in protein sequence and are mutually exclusive, since individual SWI/SNF chromatin remodeling complexes can contain either ARID1A or ARID1B but not both. Experiments aimed at validating results from the dependency screen showed that knocking down ARID1B specifically impaired the proliferation of ARID1A mutant cancer cells but had minimal effect on ARID1A wild-type cancer cells. Mechanistically, while loss of ARID1B had no effect on integrity of SWI/ SNF complexes in wild-type cells, in the context of ARID1A mutation, the combined absence of ARID1A and ARID1B destabilized SWI/SNF complexes and resulted in dissociation of subunits, which was associated with loss of cell proliferation.
In SMARCA4 mutant cells in the Achilles screen, SMARCA2 was found to be specifically essential , a relationship that was simultaneously and independently identified in another screen (Hoffman et al., 2014) and an earlier focused study in which the effects of SMARCA2 loss on SMARCA4 mutant cancers were directly tested (Oike et al., 2013) . Collectively, these reports suggest that the residual complexes created by SMARCA4 mutation rely on SMARCA2 as the remaining SWI/SNF ATPase subunit and thus cannot tolerate loss of SMARCA2. Notably, an aspect of the synthetic lethal relationship between SMARCA4 and SMARCA2 is distinct from that between ARID1A and ARID1B. While ARID1B loss destabilizes SWI/SNF complexes in ARID1A mutant cancers , the residual complexes remain intact following SMARCA2 loss in SMARCA4 mutant cancers (Hoffman et al., 2014; Wilson et al., 2014) . This finding suggests that, even though SWI/SNF subunits can fully associate without a catalytic ATPase subunit, the ATPase activity is required for the proliferation of the cancer cells. Collectively, these recent findings indicate that residual complexes exist in a variety of SWI/SNF mutant cancers and are essential for their growth.
While the dependency findings establish an essential role for residual SWI/SNF complexes in SWI/SNF mutant cancers, the mechanism by which these residual complexes promote cancer remains poorly understood. One conceptual possibility is that the residual complexes essentially acquire neomorphic gain of function, which alters targeting and/or remodeling and results in gene expression changes that facilitate transformation. Perhaps consistent with such a possibility, ARID1A and ARID1B have been reported to have opposing roles in regulation of proliferation in osteoblasts (Nagl et al., 2007) . Consequently, loss of ARID1A may result in excessive incorporation of ARID1B and unbalanced regulation of proliferation versus differentiation. Similarly, SMARCA4 and SMARCA2 show differential expression patterns during development (Machida et al., 2001; Singh and Archer, 2014; Zheng et al., 2004) , with SMARCA4 tending to be highly expressed in proliferating cells while SMARCA2 tends to be expressed in slowly cycling cells such as stem cells and in noncycling differentiated cells (Reisman et al., 2009 ). SMARCA4 and SMARCA2 have also been shown to interact with different transcription factors (Kadam and Emerson, 2003) and have been implicated in the differential control of cell fate (Flowers et al., 2009; Zhang et al., 2011) . In the neomorphic gain-of-function model, loss of function of SWI/SNF tumor Cancer Cell 26, September 8, 2014 ª2014 Elsevier Inc. 311
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Review suppressor subunits might be akin to oncogenic activation of residual SWI/SNF complexes. Accordingly, cancers become addicted to the residual complex resulting in differential dependency on specific subunits compared to normal cells.
The precise mechanism by which residual mutant SWI/SNF complexes contribute to oncogenesis remains an active area of investigation. It will be of interest to understand whether mutation of SWI/SNF subunits in cancer results in mistargeting of the complexes to chromatin akin to the effects of altered methylation of the SMARCC1 subunit, which affect targeting of SWI/ SNF complexes in breast cancer (Wang et al., 2014a) . It will also be important to determine whether the oncogenic effect of SWI/SNF subunit mutations arises in part from altered balance of variant SWI/SNF complexes and, furthermore, whether residual SWI/SNF complexes can properly remodel chromatin once they are bound. Additionally, as suggested by the fascinating finding that the SS18-SSX fusion functions primarily by ejecting SMARCB1 from SWI/SNF complexes , a key question is whether the cancer-associated mutations, in part, function by altering assembly of residual complexes. A major hope is that a deeper understanding of the mechanisms of mutant SWI/SNF complexes may facilitate development of targeted therapeutics.
A Surprise: Comutations
Several pieces of data suggest that such a model may be too simple. While ARID1A is perhaps the most frequently mutated SWI/SNF subunit, mutations of ARID1B have also been found in cancer Sausen et al., 2013; Shain and Pollack, 2013) . Given the finding of a synthetic lethal relationship between ARID1A inactivation and ARID1B knockdown, the prediction was that the mutation of ARID1A and ARID1B would not co-occur in the same cell line or tumor sample. Indeed, this hypothesis would seem to be a fundamental prediction of synthetic lethality: comutations should not occur. However, precisely the opposite was found: significant co-occurrence of ARID1A and ARID1B mutations, both in cancer cell lines and in primary cancers . What might account for both synthetic lethality and comutation? One possibility is that mutations in ARID1A or ARID1B, rather than leading to neomorphic gain of function, result in hypofunction of the residual complexes. In this scenario, ARID1A and ARID1B would have redundant functions with respect to tumor suppression, and, akin to the concept of haploinsufficiency, reduced levels of ARID1-whether ARID1A or ARID1B-result in impaired control of gene expression and predispose to transformation. However, retaining some amount of ARID1 function may be essential for cell survival; consequently, these mutations also result in enhanced dependence on ARID1B compared to normal cells. The mutational profile of ARID1A and ARID1B may provide support for such a model, as cancer cell lines were identified that had biallelic mutations in ARID1A in which ARID1B was either wild-type or mutant on one allele; cancer cell lines were identified with monoallelic mutations in both ARID1A and ARID1B; and, rarely, cancer cell lines were identified in which a monoallelic mutation in ARID1A was accompanied by biallelic mutations in ARID1B. However, no cancer cell lines were identified in which ARID1A and ARID1B both contained biallelic mutations consistent with an essential role for some ARID1 function.
The situation is less clear for the relationship between SMARCA4 and SMARCA2. Mutations in SMARCA4 have been reported in several types of cancer (Fukuoka et al., 2004; Medina et al., 2008; Reisman et al., 2003) and mice haploinsufficient for SMARCA4 are predisposed to mammary tumors (Bultman et al., 2008) . In contrast, SMARCA2 mutations are rare in primary tumors. Sequencing of SMARCA2 in non-melanomatous skin cancers identified a hotspot missense mutation in 3 of 16 cases (Moloney et al., 2009 ), a mutation class often associated with gain-of-function effects, although this mutation was not reported as significant in a subsequent exome study (Jayaraman et al., 2014) . Lack of SMARCA2 expression has been noted in several cancer cell lines and primary cancers (Glaros et al., 2007) , an effect challenging to interpret as in normal tissues SMARCA2 tends to be low in cells with high proliferative potential (Reisman et al., 2005) . However, while Smarca2-deficient mice have not been reported prone to spontaneous tumors, they are 15% larger than control littermates, prone to prostate hyperplasia (Shen et al., 2008) , and have increased susceptibility to tumor formation in an ethylcarbamate lung cancer model (Glaros et al., 2007) and a UV irradiation skin cancer model (Halliday et al., 2012) . Ultimately, while not frequently mutated, it is possible that SMARCA2 may have tumor suppressor capabilities in human tissues. Interestingly, some cell lines and cancers have been reported, such as the SW-13 cancer cell line, in which SMARCA4 is mutated and SMARCA2 not expressed (Dunaief et al., 1994; Strobeck et al., 2002) . Whether such cancers reflect emergence of resistance or whether the synthetic lethal relationship is in some way context dependent is unclear and an active area of investigation.
Therapeutic Potential
The synthetic lethal relationships described earlier raise potential opportunities for targeting of residual SWI/SNF complexes as a therapeutic approach for cancers with a SWI/SNF mutation ( Figure 2 ). SMARCA2 contains two domains of particular note with respect to the potential for therapeutic targeting: a bromodomain and an ATPase domain (Wu et al., 2009) . Substantial precedence has emerged for targeting of bomodomains, as the JQ1 BRD4 bromodomain inhibitor (Filippakopoulos et al., 2010) has shown promising effects in preclinical studies and clinical trials of BRD4 inhibition are now in progress (http://www. cancer.gov/clinicaltrials/search/view?cdrid=733416&version= HealthProfessional&protocolsearchid=12562170). A similar approach may be feasible for SMARCA2. While the crystal structures of the bromodomains of both SMARCA4 and SMARCA2 have been solved (Filippakopoulos et al., 2012) , further studies, such as small molecule screening, will be necessary to determine if these domains are targetable. It is important to note, however, that it is not entirely clear whether the bromodomain is essential for the function of SMARCA2, as studies have shown that SMARCA2 activity is dependent on a high-mobility-group protein I/Y-like DNA binding domain (Bourachot et al., 1999) . Alternatively, the ATPase domain of SMARCA2 could be targeted. While structures of yeast SWI/SNF complexes have been reported (Kasten et al., 2011) , structure of the mammalian complexes and ATPase domains would be useful for evaluating the potential for targeted drug development. If targetable, SMARCA2 may be a promising target, as Smarca2 knockout mice are reported viable (Reyes et al., 1998) . It is of interest that mutations of SMARCA2 have been found in some neural disorders (Ronan et al., 2013) . A recurrent SMARCA2 missense mutation has been identified in schizophrenia, where it is reported to reduce nuclear localization of SMARCA2 protein (Koga et al., 2009) . Mutations of SMARCA2 have also been identified as the basis for the human developmental disorder Nicolaides-Baraitser syndrome (NBS) (Van Houdt et al., 2012) . However, these mutations are either missense or small in-frame deletions, and never inactivating, leading to the prediction that the SMARCA2 mutations in NBS are gain of function and thus likely not predictive of the effects of targeted inhibition.
One challenge in developing an inhibitor to SMARCA2 is its homology to SMARCA4, which may make it difficult to develop a compound that inhibits SMARCA2 but not SMARCA4. As noted earlier, SMARCA4 and SMARCA2 do display differential transcription factor interactions, in part due to structural differences (Kadam and Emerson, 2003) , but it remains to be determined whether such structural differences can be effectively exploited for targeting. It is also worthy of note that three recent publications identified SMARCA4 itself as a potential therapeutic target in small cell lung cancer (Romero et al., 2014) and in Myc-driven leukemias (Buscarlet et al., 2014; Shi et al., 2013) . On the surface, this would seem a paradox-SMARCA4 having tumor suppressor activity in some contexts but specifically required for cancer maintenance in others. However, increasing data highlight the importance of context-dependent control of gene expression in cancer. Mutation of a gene encoding a SWI/SNF complex subunit results in the formation of a residual complex that is specifically dependent on other subunits and essential for the growth of the cancer. Targeting subunits of this residual complex is a newly identified therapeutic opportunity. (Nikoloski et al., 2010) . Even the canonical tumor suppressor p53, which can promote cancer via loss of function, is also associated with recurrent point mutations in cancer, some of which have been implicated as having gain-of-function oncogenic activity (van Oijen and Slootweg, 2000; Strano et al., 2007) . Consequently, context is essential, and whether therapeutic benefit might be derived from targeting SMARCA2, SMARCA4, or both remains to be determined. The relationship between ARID1A and ARID1B might also present therapeutic opportunity, as ARID1A is frequently mutated in many human cancers. A recent finding shows that stapled peptides can successfully disrupt the protein-protein interaction between EZH2 and the Polycomb PRC2 chromatin-modifying complex , and an analogous strategy might be possible to disrupt the interaction between ARID1B and SWI/SNF complexes. ARID1B has also been associated with an E3 ubiquitin ligase that mediates the monoubiquitination of histone H2B (Li et al., 2010) . Targeting the E3 ligase-associated activity of ARID1B is an approach worth considering, although it is unknown whether the E3 ligase activity plays a role in the synthetic lethality.
Several potential limitations must be considered for therapeutic targeting of residual SWI/SNF complexes. One is therapeutic window. The results of recent screens suggest that, at least in some cases, there is differential dependence on residual complex members between mutant and nonmutant cells. Whether this difference is great enough to constitute an effective therapeutic window, however, remains to be determined. There are also likely to be challenges in drug development, in both identifying essential domains and determining whether those domains can be feasibly targeted. An additional concern, given the tumor suppressor activity of several SWI/SNF subunit genes, is whether inhibition of SWI/SNF complexes might actually cause cancer. Even when considering ARID1B, in general, SWI/SNF mutant cancer cell lines remain dependent on the absence of the missing subunit. For example, reexpression of SMARCB1 in SMARCB1 mutant cancers causes cell cycle arrest (Kuwahara et al., 2010) and reexpression of SMARCA4 in SMARCA4 mutant cancers results in reversion of malignant phenotype (Romero et al., 2012; Wong et al., 2000) . Consequently, it seems likely that, should treatment with a compound that inhibits a SWI/ SNF subunit result in the formation of a cancer, such a cancer would likely remain dependent on the absence of the subunit Cancer Cell 26, September 8, 2014 ª2014 Elsevier Inc. 313
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Ultimately, for cancers driven by mutation of a gene encoding a SWI/SNF subunit, at least some of these mutations result in specific dependence on residual complex members, which in turn, may offer potential therapeutic targets (Figure 2) . Given the large number of cancers harboring SWI/SNF mutations, investigation of the dependency mechanisms and of the potential to target these complexes has possible broad cancer relevance. 
